<DOC>
	<DOCNO>NCT01323153</DOCNO>
	<brief_summary>This double-blind , randomize , placebo-controlled , multi-center study evaluate safety efficacy dalcetrapib patient hospitalize acute coronary syndrome ( ACS ) . Treatment initiate within 1 week ACS . Patients randomize receive dalcetrapib 600 mg daily oral dos match placebo . The anticipated time study treatment 20 week .</brief_summary>
	<brief_title>A Study Dalcetrapib Patients Hospitalized For An Acute Coronary Syndrome ( Dal-ACUTE )</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Dalcetrapib</mesh_term>
	<criteria>Adult patient , &gt; /=45 year age Patients admit hospital acute coronary syndrome ( ACS ) Patients receive guidelinebased medical dietary management dyslipidemia Symptomatic congestive heart failure ( NYHA Class III IV ) Clinically significant heart disease require coronary artery bypass grafting , cardiac transplantation , surgical valve repair/replacement study Uncontrolled hypertension Uncontrolled diabetes Severe anemia Concomitant treatment drug raise highdensity lipoprotein C ( HDLC ; eg niacin , fibrates )</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>